Details

Autor(en) / Beteiligte

• Zeng, Qing-Lei
• Yu, Zu-Jiang
• Gou, Jian-Jun
• Li, Guang-Ming
• Ma, Shu-Huan
• Zhang, Guo-Fan
• Xu, Jiang-Hai
• Lin, Wan-Bao
• Cui, Guang-Lin
• Zhang, Min-Min
• Li, Cheng
• Wang, Ze-Shuai
• Zhang, Zhi-Hao
• Liu, Zhang-Suo

Titel

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019

Ist Teil von

• The Journal of infectious diseases, 2020-06, Vol.222 (1), p.38-43

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier. Six patients with coronavirus 2019 disease and respiratory failure received convalescent plasma a median of 21.5 days after first detected viral shedding, all tested negative for severe acute respiratory syndrome coronavirus 2 within 3 days after infusion, and 5 eventually died.